Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 10/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.36 |
| ▸ | F2 | P00734 | 4/20 | 0.33 |
| ▸ | APP | P05067 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | SULT1A1 | P50225 | 1/20 | 0.31 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.31 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8289975 | 0.79 | ESR1 (0.39) | ESR1ESR2 | |
| SCHEMBL5196415 | 0.71 | ESR1 (0.43) | ESR1ESR2 | |
| SCHEMBL5244202 | 0.68 | ESR1 (0.48) | ESR1ESR2HDAC3HDAC1HDAC2 | |
| SCHEMBL5241179 | 0.68 | ESR1 (0.48) | ESR1ESR2MAPT | |
| SCHEMBL29980342 | 0.66 | HTT (0.44) | ESR1ESR2MAPT | |
| SCHEMBL3874783 | 0.66 | HTT (0.44) | ESR1ESR2MAPT | |
| SCHEMBL1616936 | 0.65 | ESR1 (0.51) | ESR1ESR2HDAC3HDAC1HDAC2 | |
| SCHEMBL20708908 | 0.65 | ESR1 (0.38) | ESR1ESR2 | |
| SCHEMBL15211201 | 0.65 | HTT (0.45) | ESR1ESR2MAPT | |
| SCHEMBL5038858 | 0.65 | ESR1 (0.45) | ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7923457-B2 | Quinoline derivatives | AGOURON PHARMACEUTICALS INC. (US) | 2011-04-12 | — | — | US | disclosed |
| US-20090069316-A1 | NOVEL QUINOLINE DERIVATIVES | AGOURON PHARMACEUTICALS, INC. | 2009-03-12 | — | — | US | disclosed |
| US-7381824-B2 | Quinoline derivatives | AGOURON PHARMACEUTICALS, INC. (US) | 2008-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069316-A1 | NOVEL QUINOLINE DERIVATIVES | COQ8B, COQ8A, MCM5 | ESR1 2896/4885ESR2 3326/4885F2 1711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.